We are live on ! Find out more
SC

Stempoint Capital Portfolio holdings

AUM $522M
1-Year Est. Return 281.95%
This Fund
S&P 500
This Quarter Est. Return
-10.52%
1 Year Est. Return
+281.95%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$314M
AUM Growth
-$86.9M
Cap. Flow
-$24.2M
Cap. Flow %
-7.71%
Top 10 Hldgs %
50.55%
Holding
86
New
32
Increased
12
Reduced
15
Closed
25

Top Buys

Rank Stock Value
1
ACLX
Arcellx
ACLX
+$18.5M
2
SRRK icon
Scholar Rock
SRRK
+$15.4M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$13.5M
4
QURE icon
uniQure
QURE
+$8.99M
5
CGON icon
CG Oncology
CGON
+$8.15M

Top Sells

Rank Stock Value
1
SNDX icon
Syndax Pharmaceuticals
SNDX
+$18M
2
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$16.2M
3
INCY icon
Incyte
INCY
+$13.4M
4
MRUS
Merus
MRUS
+$11.7M
5
PRAX icon
Praxis Precision Medicines
PRAX
+$10.3M

Sector Composition

Rank Sector Weight
1 Healthcare 99.31%
2 Financials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROIV icon
1
Roivant Sciences
ROIV
$24.8B
$26M 8.29%
2,578,860
-133,918
-5% -$1.45M
SNDX icon
2
Syndax Pharmaceuticals
SNDX
$2.02B
$19.6M 6.26%
1,598,594
-1,274,007
-44% -$18M
SRRK icon
3
Scholar Rock
SRRK
$6.33B
$18.2M 5.8%
566,212
+399,905
+240% +$15.4M
ACLX
4
DELISTED
Arcellx
ACLX
$18M 5.73%
+273,774
New +$18.5M
MRUS
5
DELISTED
Merus
MRUS
$14.6M 4.65%
346,756
-268,056
-44% -$11.7M
IMVT icon
6
Immunovant
IMVT
$8.27B
$14.6M 4.65%
853,472
-265,036
-24% -$5.54M
MDGL icon
7
Madrigal Pharmaceuticals
MDGL
$12.8B
$13.6M 4.32%
+40,936
New +$13.5M
NUVL
8
DELISTED
Nuvalent
NUVL
$13.5M 4.3%
190,401
+45,167
+31% +$3.53M
RVMD icon
9
Revolution Medicines
RVMD
$39.6B
$11.3M 3.59%
318,782
+125,247
+65% +$5.08M
JANX icon
10
Janux Therapeutics
JANX
$992M
$9.24M 2.94%
342,062
+196,186
+134% +$7.4M
XENE icon
11
Xenon Pharmaceuticals
XENE
$6.6B
$9.21M 2.94%
274,633
-101,212
-27% -$3.84M
DNLI icon
12
Denali Therapeutics
DNLI
$3.7B
$9.07M 2.89%
667,078
+82,750
+14% +$1.59M
CNTA
13
DELISTED
Centessa Pharmaceuticals
CNTA
$8.53M 2.72%
593,335
-48,629
-8% -$796K
QURE icon
14
uniQure
QURE
$2.77B
$7.75M 2.47%
731,039
+641,039
+712% +$8.99M
BBIO icon
15
BridgeBio Pharma
BBIO
$15.9B
$7.21M 2.3%
+208,437
New +$7.03M
CGON icon
16
CG Oncology
CGON
$6.34B
$7.1M 2.26%
+289,823
New +$8.15M
SWTX
17
DELISTED
SpringWorks Therapeutics
SWTX
$7.03M 2.24%
+159,305
New +$7.33M
ARQT icon
18
Arcutis Biotherapeutics
ARQT
$3.56B
$6.88M 2.19%
440,073
-60,893
-12% -$858K
INSM icon
19
Insmed
INSM
$23.5B
$6.64M 2.12%
87,059
-19,551
-18% -$1.5M
ALKS icon
20
Alkermes
ALKS
$8.79B
$6.35M 2.02%
192,352
-224,616
-54% -$7.33M
AKRO
21
DELISTED
Akero Therapeutics
AKRO
$6.32M 2.02%
+156,185
New +$6.62M
BHVN icon
22
Biohaven
BHVN
$2.32B
$6.02M 1.92%
250,564
+64,151
+34% +$2.26M
CYTK icon
23
Cytokinetics
CYTK
$10.9B
$6.01M 1.92%
149,648
+66,072
+79% +$3.04M
BPMC
24
DELISTED
Blueprint Medicines
BPMC
$5.48M 1.75%
+61,927
New +$6.04M
VTGN icon
25
VistaGen Therapeutics
VTGN
$9.4M
$5.11M 1.63%
2,366,554
+38,062
+2% +$108K
1
2 3 4

Similar funds

JE
JMAC Enterprises Newtown, Pennsylvania $522M AUM 15.34% 1-Year Est. Return
GS
GWN Securities Palm Beach Gardens, Florida $523M AUM 20.1% 1-Year Est. Return
LT
Legacy Trust Grand Rapids, Michigan $522M AUM 23.56% 1-Year Est. Return
WFA
WestHill Financial Advisors San Rafael, California $523M AUM 15.95% 1-Year Est. Return
TCM
TruNorth Capital Management Kalamazoo, Michigan $522M AUM 14.26% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
ETS
ESL Trust Services Rochester, New York $524M AUM 17.18% 1-Year Est. Return
CM
Conifer Management New York $524M AUM 14.11% 1-Year Est. Return

Stempoint Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Stempoint Capital held 86 positions worth $314M, down 22% from $401M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Stempoint Capital withdrew a net $24.2M in Q1 2025, closing 25 positions and reducing 15 holdings. Its most notable exit was Crinetics Pharmaceuticals, an estimated $16.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

Against the trend, Stempoint Capital opened a new position in Arcellx worth $18M.

  • Stempoint Capital's largest Q1 2025 buy was Arcellx: 273,774 shares worth $18M.
  • Stempoint Capital added most to Scholar Rock in Q1 2025, an estimated $15.4M increase.
  • Stempoint Capital's biggest Q1 2025 reduction was Syndax Pharmaceuticals, cutting an estimated $18M.
  • Stempoint Capital fully exited Crinetics Pharmaceuticals in Q1 2025, selling an estimated $16.2M.
  • Stempoint Capital's ten largest holdings make up 51% of its $314M portfolio in Q1 2025.
  • Stempoint Capital opened 32 new positions and closed 25 in Q1 2025.
  • Stempoint Capital's portfolio value fell 22% quarter-over-quarter to $314M.

Based on Stempoint Capital's 13F filing for Q1 2025, filed 15 May 2025.